SG Americas Securities
RYTM icon

SG Americas Securities’s Rhythm Pharmaceuticals RYTM Stock Holding History

SG Americas Securities’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.37M Buy
21,333
+2,573
+14% +$233K ﹤0.01% 1416
2026
Q1 		$1.63M Buy
18,760
+7,019
+60% +$683K ﹤0.01% 1489
2025
Q4 		$1.26M Sell
11,741
-7,813
-40% -$829K ﹤0.01% 1828
2025
Q3 		$1.98M Buy
19,554
+13,369
+216% +$1.24M 0.01% 956
2025
Q2 		$391K Sell
6,185
-13,482
-69% -$826K ﹤0.01% 1827
2025
Q1 		$1.04M Buy
+19,667
New +$1.09M ﹤0.01% 1143
2024
Q4 		– Sell
-7,519
Closed -$394K – 3553
2024
Q3 		$394K Sell
7,519
-26,208
-78% -$1.26M ﹤0.01% 1905
2024
Q2 		$1.39M Buy
33,727
+26,214
+349% +$1.05M 0.01% 1141
2024
Q1 		$326K Buy
7,513
+13
+0.2% +$569 ﹤0.01% 1643
2023
Q4 		$345K Sell
7,500
-37,374
-83% -$1.18M ﹤0.01% 1713
2023
Q3 		$1.03M Buy
+44,874
New +$1M 0.01% 1241
2022
Q3 		– Sell
-80,064
Closed -$332K – 3505
2022
Q2 		$332K Sell
80,064
-5,118
-6% -$28K ﹤0.01% 2314
2022
Q1 		$981K Sell
85,182
-6,477
-7% -$56.8K 0.01% 1444
2021
Q4 		$915K Sell
91,659
-17,644
-16% -$198K 0.01% 1717
2021
Q3 		$1.43M Buy
109,303
+27,435
+34% +$419K 0.01% 1590
2021
Q2 		$1.6M Sell
81,868
-4,916
-6% -$102K 0.01% 1259
2021
Q1 		$1.85M Sell
86,784
-23,904
-22% -$693K 0.01% 1100
2020
Q4 		$3.29M Buy
110,688
+20,390
+23% +$518K 0.02% 759
2020
Q3 		$1.96M Buy
+90,298
New +$2.07M 0.01% 752
2020
Q2 		– Sell
-11,382
Closed -$173K – 3831
2020
Q1 		$173K Sell
11,382
-3,837
-25% -$68.7K ﹤0.01% 2609
2019
Q4 		$349K Sell
15,219
-56,422
-79% -$1.25M ﹤0.01% 2071
2019
Q3 		$1.55M Buy
+71,641
New +$1.54M 0.01% 1136

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SG Americas Securities's RYTM Position: Q2 2026 in Review

SG Americas Securities increased its Rhythm Pharmaceuticals (RYTM) stake by 14% in Q2 2026, buying an estimated $233K and bringing the position to 21,333 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #1416.

SG Americas Securities first reported a position in RYTM in Q3 2019 and has held it in 22 quarters since. The position peaked at $3.29M in Q4 2020. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • SG Americas Securities held 21,333 shares of Rhythm Pharmaceuticals worth $2.37M as of Q2 2026.
  • SG Americas Securities bought 2,573 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $233K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #1416 holding.
  • SG Americas Securities first reported a position in Rhythm Pharmaceuticals in Q3 2019 and has held it in 22 quarters since.
  • SG Americas Securities's Rhythm Pharmaceuticals position peaked at $3.29M in Q4 2020.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.